St. Jude launching Angstrom II and Contour II ICDs by March 1.
This article was originally published in The Gray Sheet
Executive Summary
ST. JUDE MEDICAL's ANGSTROM II, CONTOUR II ICD MARKET LAUNCH is anticipated by March 1, the firm reports Feb. 9. The products were approved by FDA Feb. 2 via premarket approval application supplements. The Angstrom II, with a volume of 44 cc, is the smallest implantable cardioverter defibrillator on the market, while the 57 cc Contour II is the most powerful, with up to 42 joules of maximum stored energy.
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.